Why the study?
Dyslipidemias are a major determinant of cardiovascular risk in Cameroon, but the direct application of international recommendations remains limited by local socio-economic and epidemiological specificities.
This multidisciplinary expert consensus provides a pragmatic, locally adapted framework for managing dyslipidemia in Cameroon to help reduce cardiovascular morbidity and mortality.
Answers are grounded in this paper and cite their sources.
Guides statin prescribing and LDL-C targets for high- and very high-risk patients in Cameroon; extends international dyslipidemia guidelines to sub-Saharan African settings.
Dyslipidemias are a major determinant of cardiovascular risk in Cameroon, in a context of epidemiological transition marked by the increase in hypertension, diabetes, and obesity. The direct application of international recommendations remains limited by local socio-economic and epidemiological specificities. We developed a national consensus for the management of dyslipidemia in Cameroon. A multidisciplinary panel of Cameroonian experts (cardiologists, endocrinologists, neurologists, nephrologists, and internists) developed these recommendations. The methodology was based on a systematic review of international guidelines (ESC/EAS, ACC/AHA), followed by a phase of local applicability analysis and structured debates to reach a unanimous agreement. The consensus recommends systematic stratification of cardiovascular risk using World Health Organization (WHO) charts adapted for sub-Saharan Africa. Non-high-density lipoprotein cholesterol (HDL cholesterol) is favored as the first-line atherogenic marker. Statins constitute the basic treatment, with LDL-cholesterol targets of <0.70 g/L for high risk and <0.55 g/L for very high risk. Atorvastatin is proposed as the reference molecule due to its efficacy, availability, and safety profile. Specific recommendations are formulated for diabetes, stroke, and chronic kidney disease. This consensus proposes a harmonized and pragmatic framework for the management of dyslipidemias in Cameroon, likely to contribute to the reduction of cardiovascular morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Kingué et al. (2026) studied Dyslipidemias. Statins (Atorvastatin as reference molecule) was evaluated on LDL-cholesterol target attainment (<0.70 g/L for high risk and <0.55 g/L for very high risk). The Cameroonian multidisciplinary expert consensus recommends statins (with atorvastatin as the reference molecule) targeting LDL-cholesterol <0.70 g/L for high risk and <0.55 g/L for very high risk.
Synapse has enriched 10 related papers. Consider them for comparative context: